AIM
PACB icon

ARK Investment Management’s Pacific Biosciences PACB Stock Holding History

ARK Investment Management’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-7,200
Closed -$42K – 241
2022
Q3 		$42K Hold
7,200
– – ﹤0.01% 243
2022
Q2 		$41K Hold
7,200
– – ﹤0.01% 346
2022
Q1 		$66K Sell
7,200
-10,400
-59% -$120K ﹤0.01% 346
2021
Q4 		$360K Buy
17,600
+1,000
+6% +$24.1K ﹤0.01% 279
2021
Q3 		$424K Buy
+16,600
New +$492K ﹤0.01% 281

Other funds holding PACB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

ARK Investment Management's PACB Position: Q1 2026 in Review

ARK Investment Management reduced its Pacific Biosciences (PACB) stake by 2.7% in Q1 2026, selling an estimated $1.77M and leaving 36,273,288 shares worth $47.9M. The position accounts for 0.37% of the portfolio, ranked #52.

ARK Investment Management first reported a position in PACB in Q3 2017 and has held it in 33 quarters since. The position peaked at $739M in Q4 2020. 230 funds tracked by Wall St. Rank hold PACB as of Q1 2026.

  • ARK Investment Management held 36,273,288 shares of Pacific Biosciences worth $47.9M as of Q1 2026.
  • ARK Investment Management sold 990,940 Pacific Biosciences shares in Q1 2026, an estimated $1.77M.
  • Pacific Biosciences made up 0.37% of ARK Investment Management's portfolio in Q1 2026, its #52 holding.
  • ARK Investment Management first reported a position in Pacific Biosciences in Q3 2017 and has held it in 33 quarters since.
  • ARK Investment Management's Pacific Biosciences position peaked at $739M in Q4 2020.
  • 230 funds tracked by Wall St. Rank held Pacific Biosciences as of Q1 2026.

Based on ARK Investment Management's 13F filing for Q1 2026, filed 12 May 2026.